CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 524 enrolled
Drug / intervention
GSK1024805A +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00624819
NCT00624819Phase 3Completed
CompareCT.gov

Long-term Follow-up Study to Assess Antibody Persistence in Children Previously Vaccinated With Four Doses of Pneumococcal Conjugate Vaccine in Primary Vaccination Study (105553) and Booster Vaccination Study (107046)

GlaxoSmithKline·interventional·Posted Feb 27, 2008·Updated Jan 27, 2021

In Brief

A Phase 3 clinical trial evaluating GSK1024805A, Prevenar, and 3 other interventions for Infections, Streptococcal and Streptococcus Pneumoniae Vaccines. Completed, enrolled 524 participants across 6 sites.

Detailed Summary

This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who received previously 4 doses of pneumococcal conjugate vaccine. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307554). This Protocol posting has been updated in order to comply with the FDA AA (Sep 2007).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Streptococcal, Streptococcus Pneumoniae Vaccines
CountriesPoland
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 27, 2008
Enrollment StartMar 3, 2008
Primary CompletionJun 2, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.3 years ago

Interventions

GSK1024805Abiological

No vaccination in this trial

Prevenarbiological

No vaccination in this trial

Infanrix hexabiological

No vaccination in this trial

Havrixbiological

No vaccination in this trial

Varilrixbiological

No vaccination in this trial